Background: Survival analysis is a standard methodology to assess progress in oncology disease treatment.
introduction
Cumulative survival [1] and gains in life expectancy [2, 3] are standard indices to assess improvements in cancer survival. In studies of cancer survival, it is common to report the results as cumulative survival percentages at fixed intervals from diagnosis (e.g. 5 years) or as the time when the cumulative survival reaches a given (e.g. 50%, median) value. Although the cumulative survival method has some shortcomings [2] , it is the standard presentation of survival data.
An alternative way to address the issue of changes in survival is the estimation of gain in life expectancy [2, 3] . It has been suggested that this measure may be more relevant and useful for health policy makers [2, 4] .
Life expectancy is usually computed on the basis of the period under observation, but the resulting information is incomplete when considering diseases with a high proportion of long-term survivors at the end of follow-up. This situation is common in studies of survival after diseases occurring at young ages, unless prognosis is very poor. Although the findings on the increase in mean number of life years observed during the actual follow-up period (i.e. the mean number of person-years contributed by study subjects) are clear, these do not correspond to the information expected by clinicians, patients and the public at large, who focus on life expectancy from birth (or from date of diagnosis) to death rather than on the number of life years gained during an arbitrary period of follow-up. In order to overcome this problem, life expectancy can be estimated using a two-step procedure [5] : first, to estimate the life expectancy in the follow-up period and, secondly, to estimate the life expectancy for the later periods (still not observed) estimated from appropriate external sources. We suggest that this method of presenting the findings may be a useful addition to the standard approach of cumulative survival. General population life tables can be used for estimating the life expectancy for the later periods when there is evidence that after the period of follow-up the same mortality rates of the general population apply to the subjects under study (the subjects are 'cured'). This is the situation with childhood acute lymphoblastic leukemia (ALL) after a follow-up of 10 years with no adverse events [6] .
In this paper, we compute population-based life expectancy of children with ALL according to the two-step method and apply it to the evaluation of results by a period of diagnosis (a proxy of corresponding therapy regimen).
The study is based on data provided by the Childhood Cancer Registry of Piedmont (CCRP) [7, 8] . Periods of diagnosis refer to the therapeutic protocols for childhood ALL established by the Italian Association for Pediatric Hematology and Oncology (AIEOP), as considered in a previous paper [9] .
materials and methods
Since 1967 the CCRP has provided population-based periodical estimates of cancer incidence and survival in the childhood (age 0-14 years) population of the Piedmont region (north-western Italy). Procedures for data collection, follow-up, classification and data processing, as well as criteria for inclusion in the CCRP database, have been reported elsewhere [7, 8] [9] . Since the three periods have different follow-up lengths, the mean survival times cannot be compared directly. We therefore truncated the length of follow-up at 13.2 years from diagnosis to equalize the length of observation for the three subgroups.
Life expectancy for a group of subjects of the same age at time t i is [10] :
where s i is the number of individuals who are alive at time t i and L j is the number of person-years (years of life) in the jth interval starting from time t i . For a given time interval L i of length h, the number of person-years can be computed as:
Therefore, substituting (2) in (1) with constant h, we obtain:
and
Life expectancy was evaluated as a function of years from diagnosis, since the number of years from diagnosis is equivalent to the number of years of ageing.
We employed three different models, based on the Weibull [11] , exponential [11] and Gompertz [10, 12] parametric functions [13] , to estimate the cumulative survival (S) for each of the three periods of diagnosis. The assessment of fit of the model was carried out for each of them through successive steps. First, a visual examination of the agreement between survival curves as estimated by the model and by the nonparametric Kaplan-Meier method was used [14] . The test proposed by Maller and Zhou [15] , which calculates the correlation coefficient r to test the fit, was then applied for model selection. Statistical significance of the differences in cumulative survival among periods was tested using the log-rank statistic for homogeneity [1] .
Measuring the observed life expectancy after a disease requires a long period of observation. In the present case the period of observation spans over a maximum of 25 years and, by design, age at the end of follow-up cannot exceed 39 years (i.e. those cases that were diagnosed at age 14 in 1979 and were alive at the end of follow-up). Therefore lifespan cannot be measured directly for the cases alive at the end of follow-up. In order to estimate life expectancy after the end of follow-up, we added the life expectancy for the general population to the number of person years for the subjects alive at 13.2 years since diagnosis (based on his/her age at the end of follow-up).
Average expected life span (AELS) for a group of subjects was estimated as:
where a is mean age at diagnosis, over the number of subjects entering in the study; b is mean life expectancy during the follow-up period (truncated at 13.2 years) over the number of subjects entering in the study, calculated using (4). In computational terms, b is the integral under the survival curve as modeled by the selected parametric model; and c is the mean life expectancy after the follow-up period. For the children alive after 13.2 years of follow-up, the individual contribution to the term is the life expectancy for the Italian general population of the corresponding gender, age and period [16] [17] [18] , while for deceased subjects the individual contribution is 0. In computational terms, c is the product of the cumulative survival at 13.2 years in the cohort of cases by the life expectancy for the Italian general population (weighted average according to the frequency distribution of subjects by gender and age at the end of follow-up).
The summed elements (a, b, c) have the dimension of the average number of person-years, computed for the same number of subjects.
The analyses were conducted with STATA Software (version 7.0). Special attention was paid to the treatment of censored data in the integral function.
results Table 1 provides descriptive information on the data used in this analysis. Survival at 5 years (estimated by the Kaplan-Meier method) was 69.5% (95% CI 64.3% to 74.7%). It increased in the three time periods from 58.6% (95% CI 48.9% to 68.3%) to 71.3 (95% CI 63.0% to 79.6%) and to 79.1 (95% CI 70.8% to 87.5%) [log rank (LR) test, P = 0.002]. Girls showed a small and non-statistically significant advantage over boys in all periods except the first (first period: girls 55.6%, boys 61.1%, LR test P = 0.46; second period: girls 74.1%, boys 68.4%, LR test P = 0.27; third period: girls 81.8%, boys 76.6%, LR test P = 0.32).
In none of the three periods did exponential (E) and Weibull (W) models fit the data as well as the Gompertz (G) model, as indicated by Maller and Zhou's test [15] . Correlation coefficients for the models adapted to data of the first (second and third) periods were: r E = 0.938, r W = 0.969, r G = 0.996 (r E = 0.939, r W = 0.979, r G = 0.999; r E = 0.919, r W = 0.964, r G = 0.996). The Gompertz model was therefore chosen for the life expectancy analyses.
Life expectancy estimations for each time period of diagnosis were calculated after stratifying by gender. Table 2 presents the original article Annals of Oncology mean age at diagnosis ('a'), mean life expectancy during the follow-up period ('b') (truncated at 13.2 years) and mean life expectancy after the end of follow-up ('c'), by period of diagnosis and gender. The cohorts were homogeneous in terms of age at diagnosis ('a' similar across periods, slightly higher for boys than for girls). The mean life expectancies during the follow-up period ('b') increased across periods for both genders. In the last two cohorts, girls showed higher 'b' values than boys, but this was reversed for patients diagnosed in the first period. A similar pattern was observed for the mean life expectancies after the end of follow-up ('c'), which exhibit a positive temporal trend consistently for both genders, and higher values for girls in the first period. Figure 1 summarizes the computation of AELS by gender and period, with estimates resulting from adding the terms in Table  2 . Compared to boys (and girls in brackets) with ALL diagnosed in the first time period, boys (girls) with ALL diagnosed in the second time period gained 4.9 (19.0) years of life, and boys (girls) with cancer diagnosed in the third time period gained 12.2 (26.5) years.
discussion
Life expectancy methodology has been adapted from demography and used in the medical field to produce measures relevant to a wide range of issues relevant to clinicians, to health economists, policy makers and to insurance companies. Changes in life expectancy can be used to evaluate, on one hand, the disease impact on a population (studies for allocation of research funding and health services) [4] , and on the other hand, the effectiveness of medical interventions (cost-effectiveness studies of clinical trials and preventive services) [2, 5] .
In order to evaluate the effect of different treatment protocols employed in subsequent calendar periods, we have compared 
Annals of Oncology original article
life expectancy across groups of patients diagnosed in those periods. Contrary to other authors [19] , we consider life expectancy to be a suitable population-based indicator even when obtained from observational studies in which some members of the cohort are still alive at the end of follow-up, provided that it is reasonable to assume that the life expectancy of the study participants after the end of follow-up is the same as that of the general population. Messori et al. [5] proposed to extrapolate 'to infinity' traditional survival curves in different clinical trials settings. In contrast, we applied to populationbased data a method for estimating the total number of years of life expected after the period of follow-up using populationbased life tables. The approach is useful in studies of diseases with unchanged survival probabilities after the period of observation, as in the case of childhood ALL in recent years. Of course it is less relevant to diseases that are fatal for almost all patients within the observation period [3, 19] , or for which it is not reasonable to assume that life expectancy after the end of follow-up will be the same as for the general population. We addressed the issue of comparing groups that possibly have different prognosis using a two-step procedure: first, we estimated life expectancy during the period of observation and then we added our best available estimate of future life expectancy for the long-term survivors of the disease.
Regarding the first step, we estimated survival according to the Gompertz [19] model and derived life expectancy from the estimated parameters. In the context of life expectancy evaluation, other authors used parametric models such as exponential [3] or Gompertz [19] , in preference to the nonparametric (K-M) approach when achieving good fit to data. The choice of the Gompertz model was the result of testing the adequacy of fit of this model compared with both exponential and Weibull.
With regards to the second step, the selection of the model for the extrapolation after the end of the observed period is critical, as observed by both Wright et al. [2] and Messori et al. [5] . We computed life expectancy using the demographic estimate [16] [17] [18] for the general population, i.e. under the assumption that the 'plateau' observed in cumulative survival for ALL after 10 years for all the study periods will remain stable [6] . This is the most critical assumption for the present study. We consider it to be a reasonable assumption for the present purpose for several reasons. In previous analyses on the same Registry we observed that changes of the cumulative survival after 10 years since diagnosis were smaller than 2.7% [9, 20] . Consistently, other studies have shown that in children with ALL who survived for 10 years with no adverse events, survival in the following 20 years was 95.3% versus 99.7% for the general US population [6] .
In this study we observed a change in life expectancy for subjects enrolled over three subsequent periods of diagnosis, corresponding partly to observed improvements in survival [20] , but mainly to the well documented positive secular trend in the general population's life expectancy [21] . The improvements in survival of our cohorts not only affect the computation of mean life expectancies during the follow-up period, but they also account for increases in mean life expectancies after the end of follow-up ('c' terms, which are products of cumulative survivals at 13.2 years and weighted averages of the general population's life expectancy; Table 2 ). The changes in the two terms can be summed and have contributed to the increase in the number of person years (total life expectancy) for the more recent periods, consistently for boys and girls (Figure 1 ). When comparing AELS by gender, it is notable that girls show higher values than boys, for all periods of diagnosis except the first. In fact, it is known that girls with childhood leukemia show better prognosis than boys [9, 22] , and also that women on average live longer than men [16] [17] [18] . However, the first cohort of diagnosis exhibits an unusual pattern, with higher AELS for boys than for girls. This is mainly due to an advantage in survival for boys: Pastore et al. [9] previously reported a 5% difference in 5-year survival, and we observed a 9% difference in survival at 13.2 years since diagnosis. Neither of the two figures reached statistical significance, but they are still of interest. A possible difference lies in a change in the higher proportion of pre-B immunophenotype cases (at better prognosis, as consistently shown in literature [9, 23] ) among boys.
It must be kept in mind that the reported gain in life expectancy is averaged across the target population receiving the treatment (boys and girls recruited over the subsequent periods) and offers no information about the distribution of the gains in life expectancy actually realized by particular patients [2] . When we compare AELS we are considering only point estimates derived from heterogeneous groups of patients, some of whom died shortly after diagnosis and others who were 'cured'.
The limitations of this approach should also be stressed. First, as noted above, this approach can only be used for diseases and populations for which it is reasonable to assume that patient survival at the end of follow-up is similar to that in the general population. Secondly, Figure 1 shows that the increase in life expectancy across diagnosis periods was largely due to the increases in life expectancy after the end of follow-up, i.e. because of increases in general population life expectancy, and the increases in life expectancy due to improvements in treatment were relatively small. This means that the methods presented here should be regarded as a complement to, rather than a substitute for, standard methods of survival analysis, and that the findings of the analyses presented here should always be presented in their three component parts (as in Figure 1 ) rather than as a single summary figure.
In conclusion we deem that life expectancy methodology can be applied to the study of survival of many types of childhood cancer, and that the information we derive from it can be useful from a clinical and from a public health perspective.
appendix
Gompertz model: Survival function: S(t) = exp((ÿk/c)*(exp(c*t)ÿ1)) Hazard rate: h(t) = ke ct Cumulative risk: K(t) = ke ct /c Non-parametric Kaplan Meier method: Survival function: S(t) = P[(n i ÿm i )/n i ], t i £ t < t i +1 (i < k), where n i is individuals at risk and m i is individuals leaving the interval (dead, censored or lost). 
